About Lexaria Bioscience
Lexaria Bioscience is a company based in Kelowna (Canada) founded in 2004. The company has 7 employees as of August 31, 2024. Lexaria Bioscience offers products and services including DehydraTECH. Lexaria Bioscience operates in a competitive market with competitors including Focus Financial Partners, Alera Group, Avidity Biosciences, Sutro Biopharma and Wintrust, among others.
- Headquarter Kelowna, Canada
- Employees 7 as on 31 Aug, 2024
- Stage Public
-
Sectors
HealthcareFinancial Services
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lexaria Bioscience Corp.
-
Annual Revenue
$705.92 K (USD)52.05as on Aug 31, 2025
-
Net Profit
-$11.9 M (USD)-105.37as on Aug 31, 2025
-
EBITDA
-$11.52 M (USD)-104.97as on Aug 31, 2025
-
Latest Funding Round
$1.57 M (USD), Post-IPO
Oct 04, 2023
-
Investors
Not available
-
Employee Count
7
as on Aug 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lexaria Bioscience
Lexaria Bioscience is a publicly listed company on the NASDAQ with ticker symbol LEXX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lexaria Bioscience
Lexaria Bioscience offers a comprehensive portfolio of products and services, including DehydraTECH.
Platform enhances absorption of oral pharmaceuticals and reduces side effects
People of Lexaria Bioscience
Unlock access to complete
Unlock access to complete
Funding Insights of Lexaria Bioscience
Investments & Acquisitions by Lexaria Bioscience
Investment portfolio details for Lexaria Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lexaria Bioscience
Detailed financials for Lexaria Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lexaria Bioscience Comparisons
Peer comparison for Lexaria Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lexaria Bioscience
Lexaria Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Focus Financial Partners, Alera Group, Avidity Biosciences, Sutro Biopharma and Wintrust, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Business consulting services are provided to banks and lending institutions.
|
|
| Locked | Locked | Locked |
HR, insurance, and liability services are provided by Alera Group.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Bank offering diversified financial services
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
Detailed competitors of Lexaria Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lexaria Bioscience
Complete news archive for Lexaria Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lexaria Bioscience
Lexaria Bioscience was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Lexaria Bioscience is headquartered in Kelowna, Canada. It is registered at Kelowna, British Columbia, Canada.
Chris Bunka is the current CEO of Lexaria Bioscience.
As of Aug 31, 2024, the latest employee count at Lexaria Bioscience is 7.
Annual revenue of Lexaria Bioscience is $705.92K as on Aug 31, 2025.
Lexaria Bioscience was founded in 2004 in Kelowna, Canada, within the biotechnology sector. Patented DehydraTECH technology is utilized for delivering fat-soluble active molecules and drugs, encompassing nicotine, NSAID pain-relievers, and other bioactives. Operations focus on formulation and delivery methods, with topical products such as patches, creams, and lotions also developed for administration.
Lexaria Bioscience's top competitors include Sutro Biopharma, Focus Financial Partners and Alera Group.
Lexaria Bioscience offers DehydraTECH.
Yes, Lexaria Bioscience is publicly traded on NASDAQ under the ticker symbol LEXX.
The ticker symbol of Lexaria Bioscience is LEXX on NASDAQ.